Neil Kumar, BridgeBio CEO (California Life Sciences via YouTube)
March 29, 2022 02:35 PM EDT
Pharma
Law

Af­ter rais­ing claims Bridge­Bio wild­ly over­paid di­rec­tors, the ac­cuser wants a $4M re­ward

Nicole DeFeudis

Editor

Back in May of last year, a Bridge­Bio in­vestor filed a com­plaint al­leg­ing that the com­pa­ny’s board of di­rec­tors — home to a few of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

A service from the Financial Times